Clinical Trials Browser

Completed × Cetuximab × CNS × Clear all

NCT01012609 2022-03-14

External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas

Phase 2 Completed

47 enrolled 18 charts

CNS

Brain Neoplasms

NCT01238237 2017-02-01

Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA

Phase 1 Completed

15 enrolled

CNS

Astrocytoma, Brain Neoplasms, Glioblastoma

NCT00397384 2015-09-30

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

Phase 1 Completed

43 enrolled

CNSGastrointestinalHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Tongue Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors

NCT00101348 2014-06-11

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Phase 1/2 Completed

66 enrolled

CNSGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory

NCT00463073 2008-12-11

Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas

Phase 2 Completed

32 enrolled

CNS

Glioma